- Home
- PROF vs YMAB Comparison
PROF vs YMAB Comparison
Compare PROF & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROF
- YMAB
- Stock Information
- Founded
- PROF N/A
- YMAB 2015
- Country
- PROF Canada
- YMAB United States
- Employees
- PROF N/A
- YMAB N/A
- Industry
- PROF Medical/Dental Instruments
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PROF Health Care
- YMAB Health Care
- Exchange
- PROF Nasdaq
- YMAB Nasdaq
- Market Cap
- PROF 201.2M
- YMAB 218.4M
- IPO Year
- PROF N/A
- YMAB 2018
- Fundamental
- Price
- PROF $4.56
- YMAB $4.82
- Analyst Decision
- PROF Strong Buy
- YMAB Buy
- Analyst Count
- PROF 1
- YMAB 11
- Target Price
- PROF $12.00
- YMAB $18.73
- AVG Volume (30 Days)
- PROF 99.5K
- YMAB 265.6K
- Earning Date
- PROF 05-08-2025
- YMAB 05-06-2025
- Dividend Yield
- PROF N/A
- YMAB N/A
- EPS Growth
- PROF N/A
- YMAB N/A
- EPS
- PROF N/A
- YMAB N/A
- Revenue
- PROF $10,680,000.00
- YMAB $87,685,000.00
- Revenue This Year
- PROF $165.23
- YMAB N/A
- Revenue Next Year
- PROF $96.94
- YMAB $21.10
- P/E Ratio
- PROF N/A
- YMAB N/A
- Revenue Growth
- PROF 48.35
- YMAB 3.38
- 52 Week Low
- PROF $3.90
- YMAB $3.86
- 52 Week High
- PROF $11.42
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- PROF 25.54
- YMAB 49.76
- Support Level
- PROF $4.62
- YMAB $4.46
- Resistance Level
- PROF $4.98
- YMAB $5.44
- Average True Range (ATR)
- PROF 0.39
- YMAB 0.45
- MACD
- PROF -0.01
- YMAB 0.07
- Stochastic Oscillator
- PROF 33.02
- YMAB 60.76
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.